An Approach to the Treatment of Children With COVID-19

Alison Boast; Nigel Curtis; Johanna Holschier; Rachael Purcell; Samantha Bannister; Christine Plover; Maidhili Chinnapan; David Burgner; Suzanne L Boyce; Sarah McNab; Amanda Gwee; RCH COVID-19 Treatment Working Group

doi:10.1097/INF.0000000000003576

An Approach to the Treatment of Children With COVID-19

Pediatr Infect Dis J. 2022 Aug 1;41(8):654-662. doi: 10.1097/INF.0000000000003576. Epub 2022 Jul 13.

Authors

Alison Boast^{1

2

3}, Nigel Curtis^{1

2

3}, Johanna Holschier⁴, Rachael Purcell^{1

2}, Samantha Bannister^{1

2

3}, Christine Plover⁴, Maidhili Chinnapan¹, David Burgner^{1

2

3}, Suzanne L Boyce^{1

3}, Sarah McNab^{1

2

3}, Amanda Gwee^{1

2

3}; RCH COVID-19 Treatment Working Group

Affiliations

¹ Infectious Diseases and General Medicine, The Royal Children's Hospital Melbourne.
² Department of Paediatrics, The University of Melbourne.
³ Infectious Diseases, Inflammatory Origins and Clinical Paediatrics Research Groups, Murdoch Children's Research Institute.
⁴ Pharmacy and Medicines Information Centre, The Royal Children's Hospital Melbourne, Parkville, Australia.

Abstract

There are limited data to guide treatment recommendations for children with acute, symptomatic coronavirus disease 2019 (COVID-19). This review outlines a proposed management approach for children based on the published evidence to date and the approval of medications through drug regulatory agencies, as well as the known safety profile of the recommended drugs in this age group.

Publication types

Review

MeSH terms

COVID-19 Drug Treatment*
Child
Humans
SARS-CoV-2